Neuroprotective Potential of Fenugreek and Black Cumin in Alzheimer’s Disease: A Comprehensive Review

Vishakha Tyagi¹, Yashvardhan Vats¹, Qurratul Ain¹, Vipin Kumar¹, Shabnam Ain¹*

Raj Kumar Garg² and Sneha Pandey¹

¹Sanskar College of Pharmacy and Research, Ghaziabad, U.P, India

² K. D. Medical College, Mathura, U.P, India

*Correspondence: shabnam.ain@sanskar.org; Tel.: 9310807567

DOI: https://doi.org/10.71431/IJRPAS.2025.4504

INTRODUCTION

Alzheimer’s disease, first described over a century ago, is the most common form of dementia, accounting for 60-80% of cases globally. It is characterized by the accumulation of amyloid-beta plaques and neurofibrillary tangles in the brain, leading to synaptic dysfunction, neuronal loss, and ultimately cognitive decline. [1, 3] With no cure currently available, the primary focus of AD treatment has been on managing symptoms and slowing disease progression. However, the side effects and limited efficacy of existing drugs have driven interest in alternative and complementary therapies, particularly those derived from natural sources. [2, 4]

Herbal medicine has long been used in various cultures to treat cognitive impairments, and recent scientific investigations have begun to validate the neuroprotective properties of certain plants. [1,4] Fenugreek (Trigonella foenumgraecum) and Nigella sativa (black cumin) have been extensively used in traditional medicine for their anti-inflammatory, antioxidant, and neuroprotective properties, making them promising candidates for AD treatment. This review aims to explore the scientific basis of their neuroprotective potential in Alzheimer’s, focusing on their roles in inflammation [13], oxidative stress, and neuronal protection. [3,4] Among these, Fenugreek and Nigella sativa have emerged as promising candidates due to their extensive use in traditional medicine and a growing body of evidence supporting their therapeutic potential in neurodegenerative diseases. This review seeks to provide a detailed overview of the neuroprotective mechanisms of these two herbs, their effects in preclinical models of AD, and their potential for future therapeutic use in human populations. [4]

Overview of Fenugreek and Nigella Sativa

Fenugreek (Trigonella foenum-graecum): Fenugreek is a leguminous herb commonly used in culinary and medicinal applications across Asia, the Middle East, and the Mediterranean. Its seeds are rich in bioactive compounds, including saponins, alkaloids, flavonoids, and polyphenols, which have been shown to exert various pharmacological effects. [4] Traditionally, Fenugreek has been used to treat digestive disorders, inflammation, and metabolic conditions such as diabetes. Recent studies suggest that it may also have neuroprotective properties, potentially making it a valuable addition to the treatment of neurodegenerative diseases like Alzheimer’s. [3, 5]

            Fig. 1 Fenugreek activity against neurological disorders

Nigella sativa (Black Cumin): Nigella sativa, commonly known as black cumin, is an annual flowering plant native to South and Southwest Asia. It has been used for centuries in traditional medicine, particularly in the Middle East and South Asia, for its wide range of therapeutic effects. [5, 1] The seeds contain numerous active compounds, with thymoquinone being the most studied for its potent antioxidant, anti-inflammatory, and immunomodulatory properties. Nigella sativa has been investigated for its effects on a variety of conditions, including cancer, cardiovascular diseases, and neurological disorders, with emerging evidence pointing to its potential role in protecting against Alzheimer’s disease. [2, 4]

Fig. 2 Physiological and Pharmacological Properties of Fenugreek

Pathophysiology of Alzheimer’s Disease

Alzheimer’s disease (AD) is characterized by several interrelated pathological processes that contribute to the progressive degeneration of neurons and the subsequent cognitive decline. Among the hallmark features of AD are amyloid-beta plaques and neurofibrillary tangles, but there are other critical mechanisms, including chronic inflammation, oxidative stress, and synaptic dysfunction, that all play a crucial role in disease progression. [5, 3]

1.      Amyloid-beta Plaques: One of the earliest and most significant events in AD is the accumulation of amyloid-beta peptides in the brain. These peptides aggregate into extracellular plaques that disrupt cell-to-cell communication and initiate a cascade of toxic events, including inflammation and oxidative damage. Amyloid-beta accumulation is believed to play a central role in triggering neuronal death and cognitive decline, as the plaques interfere with synaptic function and lead to a toxic environment in the brain. [5,1,11]

2.      Neurofibrillary Tangles: Inside neurons, hyperphosphorylated tau proteins aggregate to form neurofibrillary tangles. These tangles disrupt the structural integrity of neurons by interfering with microtubule function, which is essential for the proper transport of nutrients and molecules within neurons. As a result, neurons lose their ability to communicate effectively and eventually die, further contributing to the cognitive decline seen in AD. [6, 2]

3.      Chronic Inflammation: The brain’s immune response is also implicated in AD pathogenesis. Microglia, the brain’s resident immune cells, become chronically activated in the presence of amyloid plaques and tau tangles, releasing pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α. Astrocytes, another type of glial cell, also contribute to this inflammatory Response. [6, 5] This chronic neuro inflammation exacerbates neuronal damage and accelerates disease progression by creating a toxic environment that impairs the function and survival of neurons.

4.      Oxidative Stress: The brain is particularly vulnerable to oxidative stress due to its high metabolic activity and rich lipid content. In AD, the balance between the production of reactive oxygen species (ROS) and the brain’s antioxidant defences becomes disrupted. ROS cause damage to lipids, proteins, and DNA, leading to widespread cellular dysfunction and neurondeath. Oxidative stress is both a cause and consequence of amyloid-beta and tau pathology, creating a vicious cycle that drives neurodegeneration. [6,3]

5.       Synaptic Dysfunction: One of the strongest correlates of cognitive decline in AD is the loss of synaptic connections between neurons. Synaptic dysfunction occurs early in the disease process, even before widespread neuron loss, and is driven by amyloid-beta and tau pathology, as well as by inflammation and oxidative stress. This loss of connectivity between neurons is directly associated with memory impairment and other cognitive deficits observed in AD patients. [6, 2]

Fig. 3 Pathophysiology of Alzheimer ’s disease

            Fig. 4 Comparison between Normal Brain and Alzheimer Disease

Given the multifactorial nature of Alzheimer’s disease, effective therapeutic strategies must target multiple pathways simultaneously to slow or halt disease progression. Fenugreek and Nigella sativa, with their diverse array of bioactive compounds, offer potential multi-targeted neuroprotection. Through their anti-inflammatory [14, 16], antioxidant, and neurogenic properties, these herbs may modulate key pathological mechanisms such as plaque formation, oxidative damage, and synaptic dysfunction. By addressing these interconnected pathways, Fenugreek and Nigella sativa could be valuable additions to the current therapeutic landscape for Alzheimer’s disease, providing a complementary approach to conventional treatments. [6]

MECHANISMS OF ACTION IN NEUROPROTECTION

1.      Anti-Inflammatory Effects: Inflammation [12] is a major contributor to the progression of Alzheimer’s disease. Microglial cells, the primary immune cells in the brain, become chronically activated in AD, releasing proinflammatory cytokines such as IL-1β, IL-6, and TNF-α. This chronic inflammation exacerbates neuronal damage and accelerates the progression of the disease [6, 4].

Fenugreek has been shown to have significant anti-inflammatory [6, 11, 14, 16] properties, primarily through its modulation of the NF-κB signaling pathway, which is a key regulator of inflammatory responses. By inhibiting the activation of NF-κB, Fenugreek reduces the production of pro-inflammatory cytokines, potentially mitigating neuro inflammation in Alzheimer’s disease. [6, 11]

Nigella sativa, particularly its active compound thymoquinone, also exhibits potent anti-inflammatory effects. Thymoquinone has been shown to inhibit the production of pro-inflammatory cytokines and reduce the activation of microglial cells. Additionally, it can modulate the expression of COX-2 and iNOS, enzymes that play crucial roles in the inflammatory process. By reducing neuroinflammation, Nigella sativa may protect against the neuronal damage associated with Alzheimer’s disease.

2.      Antioxidant Properties: Oxidative stress is another critical factor in the pathogenesis of Alzheimer’s disease. The brain, with its high oxygen consumption and abundant lipid content, is particularly vulnerable to oxidative damage. In Alzheimer’s disease, increased levels of ROS contribute to lipid peroxidation, DNA damage, and protein oxidation, all of which exacerbate neuronal loss. [7]

Fenugreek contains a variety of antioxidant compounds, including flavonoids, polyphenols, and saponins, which help to neutralize free radicals and reduce oxidative stress. Studies have shown that Fenugreek can enhance the activity ofendogenous antioxidant enzymes such as superoxide dismutase (SOD) and catalase, further protecting neurons from oxidative damage. [7, 1]

Nigella sativa is also rich in antioxidants, with thymoquinone being the most potent. Thymoquinone has been shown to scavenge free radicals, inhibit lipid peroxidation and enhance the activity of antioxidant [15] enzymes. These effects help to protect neurons from oxidative damage and may slow the progression of Alzheimer’s Disease.

3.      Neurogenesis and Cognitive Function: In addition to reducing inflammation and oxidative stress, both Fenugreek and Nigella sativa may promote neurogenesis and improve cognitive function. Neurogenesis, the process by which new neurons are generated, is crucial for maintaining cognitive function and repairing damage in the brain. In Alzheimer’s disease, neurogenesis is often impaired, contributing to cognitive decline. [7, 2, 4, 11]

Fenugreek has been shown to improve memory and cognitive function in animal models of Alzheimer’s disease, possibly through its ability to modulate insulin signaling. Insulin resistance is a known risk factor for Alzheimer’s disease, and Fenugreek’s effects on insulin sensitivity may help to protect against cognitive decline.

Nigella sativa has also been shown to enhance memory and learning in animal models, possibly through its effects on neurotransmitter levels. Thymoquinone, in particular, has been shown to increase levels of acetylcholine, a neurotransmitter that is critical for learning and memory. By enhancing neurogenesis and improving cognitive function, Nigella sativa may help to mitigate the cognitive decline associated with Alzheimer’s disease. [1, 4, 7]

Preclinical and Clinical Studies

1.      Fenugreek Studies: Numerous preclinical studies have explored the neuroprotective effects of Fenugreek in models of Alzheimer’s disease. For example, studies have shown that Fenugreek extract can improve memory and learning in animal models, reduce the accumulation of amyloid-beta plaques, and decrease oxidative stress and inflammation in the brain. These findings suggest that Fenugreek may be a promising candidate for the treatment of Alzheimer’s disease, although more research is needed to confirm these effects in humans. [7, 2]

2.      Nigella sativa Studies: Nigella sativa, commonly known as black cumin, has garnered considerable interest for its neuroprotective potential in Alzheimer’s disease (AD), with numerous preclinical studies providing encouraging results. Animal models of AD have demonstrated that Nigella sativa can significantly improve cognitive function, potentially due to its ability to enhance neurotransmitter levels and modulate key neural pathways involved in memory and learning. Thymoquinone, the primary bioactive compound in Nigella sativa, has shown potent antioxidant properties, helping to neutralize free radicals and reduce oxidative stress a critical factor in AD progression. [8, 4]

In addition to its antioxidant effects, Nigella sativa has been found to exhibit strong anti-inflammatory actions, which are particularly relevant to Alzheimer’s disease, where chronic neuroinflammation plays a significant role. By inhibiting the release of pro-inflammatory cytokines and reducing microglial activation, Nigella sativa can mitigate inflammation-driven neuronal damage. Furthermore, preclinical research suggests that Nigella sativa may also help protect against amyloid-beta-induced neurotoxicity, one of the key factors driving neuronal degeneration in AD. [4] Studies have shown that Nigella sativa can reduce amyloid-beta accumulation, potentially through modulation of beta-secretase activity, and decrease the formation of amyloid plaques, which are a hallmark of the disease. [8, 3]

While these preclinical findings are promising, clinical studies in human populations remain limited. However, early-stage clinical trials and observational studies in older adults have indicated that Nigella sativa may have beneficial effects on cognitive function. For example, small-scale studies have reported improvements in memory, attention, and overall cognitive performance in elderly individuals who consumed Nigella sativa, suggesting its potential role in delaying cognitive decline. Additionally, its ability to enhance acetylcholine levels, a neurotransmitter critical for learning and memory, further supports its potential application in Alzheimer’s treatment. [9, 11]

FUTURE DIRECTIONS

Clinical Trials: Conducting well-designed clinical trials to evaluate the efficacy and safety of Fenugreek and Nigella sativa in human populations is crucial. These studies should aim to establish optimal dosages, formulations, and treatment durations. They should also assess the long-term effects and potential interactions with conventional Alzheimer’s medications. [9, 2]

Mechanistic Studies: Further research is needed to elucidate the precise molecular mechanisms through which Fenugreek and Nigella sativa exert their neuroprotective effects. Understanding how these herbs interact with specific cellular pathways and neurotransmitter systems will enhance their therapeutic development. [9, 4]

Standardization and Quality Control: Developing standardized extracts of Fenugreek and Nigella sativa with consistent bioactive compound levels is essential for ensuring reliable therapeutic outcomes. Quality control measures should be established to maintain the efficacy and safety of these herbal products.

Combination Therapies: Exploring the potential synergistic effects of combining Fenugreek and Nigella saliva with other natural or conventional treatments could lead to more effective and comprehensive therapeutic strategies. Studies should investigate how these herbs interact with other drugs used in Alzheimer’s disease management. [6, 5]

Mechanisms of Interaction: Research should also focus on the interactions between Fenugreek and Nigella sativa and various biological systems, including their effects on drug metabolism and potential side effects when used alongside other medications. [7, 3]

Potential for Therapeutic Application Given the neuroprotective properties of Fenugreek and Nigella sativa, there is significant potential for their use as complementary therapies in the treatment of Alzheimer’s disease. [9, 8]

    CONCLUSION

Fenugreek (Trigonella foenum-graecum) and Black Cumin (Nigella sativa) both show considerable promise in the treatment and management of Alzheimer’s disease through their multifaceted mechanisms of action. Fenugreek’s bioactive compounds, such as diosgenin, flavonoids, and alkaloids, provide neuroprotection by reducing oxidative stress, modulating inflammation, and inhibiting beta-amyloid aggregation, which are key factors in Alzheimer’s pathology. Similarly, Nigella sativa, primarily due to thymoquinone, exhibits strong antioxidant and anti-inflammatory effects, protects neurons from oxidative damage, and enhances memory and cognitive functions.

Both plants also have the potential to enhance cholinergic transmission and promote neuronal survival, which are crucial for cognitive health. Despite their promising pharmacological profiles, challenges such as limited bioavailability and the need for further clinical validation remain. Nevertheless, with advancements in drug delivery systems and continued research, Fenugreek and Black Cumin could offer valuable complementary options in the prevention or treatment of Alzheimer’s disease, contributing to a broader range of therapeutic approaches.

CONFLICT OF INTEREST

NONE

REFERENCES      

1.      Garg, Tarun Gupta, Ankur Bala, Rajni, Sharma, Poonam. (2013). Development and evaluation of herbal deodorant formulations. Journal of Cosmetic Science, 64(4), 351–360.

2.       Pankaj Sharma & Anjali Thakur (2017). Herbal cosmetics: A safe alternative to synthetic deodorants. Journal of Ayurveda and Integrative Medicine, 8(3), 187–194.

3.      Rani, Sunita, Meena, Kapil, Bhardwaj, Ritika, & Soni, Sanjay. (2018). Formulation and evaluation of a herbal deodorant stick using natural essential oils. International Journal of Pharmaceutical Sciences and Research, 9(5), 1894–1899.

4.      Umesh Kumar, Saraogi, Ruchi Pandey, Arvind. (2012). Natural antioxidants in cosmetics: Current trends and future perspectives. Journal of Medicinal Plants Research, 6(25), 4412–4426.

5.       Neha Chauhan, Nitin  Kaushik, Parul, & Yadav Harsh. (2020). Herbal cosmetics: A review on formulations and evaluation. Journal of Cosmetic Dermatology, 19(2), 343–350.

6.       Swati Saini, Vikas Bansal, Sunita Kumar, Anil Agarwal (2015). Antimicrobial and deodorizing properties of essential oils in herbal deodorant formulations. International Journal of Cosmetic Science, 37(5), 467–473.

7.      Dinesh, Deepak Verma, Ritu Patel, Rakesh Saxena, Shraddha. (2016). Evaluation of herbal formulations as natural deodorants. Indian Journal of Pharmaceutical Education and Research, 50(3), 503–509.

8.      Vikram Srivastava, Neelam Tiwari, Anamika Mishra, Ramesh Kumar (2018). Essential oils as a natural alternative for deodorant formulations: A review. Journal of Essential Oil Research, 30 (1), 1–15.

9.      Shalini Singh, Priya Jain (2014). Development of herbal deodorant with antimicrobial properties. Asian Journal of Pharmaceutical Research and Development, 2(2), 98–103.

10.  Saurabh Mishra, Sangeeta Kumari (2021). Sustainable and eco-friendly herbal deodorant formulation: Development and evaluation. International Journal of Green Pharmacy, 15(1), 25–32

11.  Sneha Pandey, Vipin Kumar, Shabnam Ain, Qurratul Ain, Babita Kumar, Nidhi Ruhela, Bhuvnesh. (2025). Alzheimer’s disease: An Overview. International Journal of Research in Pharmacy and Allied Science, 4(2), 13-32.

12.  Sneha Pandey, Vipin Kumar, Shabnam Ain, Qurratul Ain, Bhuvnesh, Nidhi Ruhela, Chhavi Nagar, Babita Kumar. (2025). Impact of Heavy Metals on Respiratory Disease. International Journal of Research in Pharmacy and Allied Science, 4(3), 1-12.

13.  Mehtab Ali, Shabnam Ain, Babita Kumar, Qurratul Ain. (2022). Development and evaluation of eugenol-based gel formulation for analgesic and anti-inflammatory action. Annals of Phytomedicine, 11(1): 338-345.

14.  Parvesh Kumar Dhama, Shabnam Ain, Babita Kumar, Qurratul Ain. (2022). Development and evaluation of topical ointment formulation containing gallic acid as an active pharmaceutical ingredient against bacterial infection and oxidative damage. Annals of Phytomedicine, 11(11): 439-449.

15.  Shabnam Ain, Gaurav Mishra, Babita Kumar, Qurratul Ain, Raj Kumar Garg. (2022). Antidiabetic Potential of Developed Solid Lipid Nanoparticles Loaded with Quercetin: in-vitro and in-silico Studies. Annals of Phytomedicine, 11(2): 1-11.

16.  Zulekha Ali, Shabnam Ain, Shalini Sharma, Qurratul Ain, Babita Kumar. (2025). Recent Advances in Osteoarthritis: Pathophysiology, Diagnosis, and Therapeutic Strategies. Cuestiones de Fisioterapia, 54 (2), 787-811